The European Society for Medical Oncology (ESMO) Congress 2025 will be held from October 17-21 (local time) in Berlin, Germany, bringing together cutting-edge concepts and the latest breakthroughs in international oncology research and treatments. 

Affinity Biopharma’s first Phase III registration trial of Legubicin, an independently developed, Tumor MicroEnvironment–Activated (TMEA) small molecule/ albumin-drug conjugate, has been selected as the Late-Breaking Abstract (LBA) at ESMO. The data will be presented for the first time during the Proffered Paper Session: Sarcoma on October 19 (local time). This clinical trial is a first-line, randomized, double-blind, head-to-head pivotal study of Legubicin versus doxorubicin in soft tissue sarcoma indication. Meanwhile, Legubicin continues to be explored in clinical studies across multiple cancer types.

Details of the Oral Presentation:

·        Abstract Number: LBA97

·        Title: Legubicin versus doxorubicin (DOX) in patients (pts) with advanced soft tissue sarcoma (STS): results of a randomized Phase II/III study

·        Speaker: Zan Shen (Shanghai Sixth People’s Hospital)

·        Session: Proffered Paper Session: Sarcoma

·        Presentation Time (local): October 19, 2025, 16:30–16:40 (Beijing Time: 22:30–22:40)

·        Location: Dortmund Auditorium – Hall 7.1a